Neurocrine reports Phase 2 fail for depression drug it licensed from Takeda

Neurocrine Biosciences said that a candidate for major depressive disorder that it got from Takeda did not succeed in a mid-stage trial. The oral drug, codenamed NBI-1070770, did not meet the primary endpoint. This used ...